International Journal of Clinical Oncology最新文献

{"title":"Immune checkpoint inhibitors in the treatment of pleural mesothelioma: insights from real-world data.","authors":"Masatoshi Kanayama, Takehiko Manabe, Katsuma Yoshimatsu, Rintaro Oyama, Hiroki Matsumiya, Masataka Mori, Masaru Takenaka, Koji Kuroda, Fumihiro Tanaka","doi":"10.1007/s10147-025-02706-4","DOIUrl":"10.1007/s10147-025-02706-4","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) have recently emerged as a promising strategy for the treatment of pleural mesothelioma (PM).</p><p><strong>Methods: </strong>This retrospective study evaluated treatment efficacy and safety in Japanese patients with PM treated with nivolumab and ipilimumab (N + I group: 41 patients) as first-line therapy and nivolumab monotherapy (N group: 33 patients) as second- or later-line treatment.</p><p><strong>Results: </strong>The median overall survival (OS) and progression-free survival (PFS) were not reached and 10.4 months in the N + I group, and 8.6 months and 3.5 months in the N group, respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 68.3% of the N + I group and 72.7% of the N group, with grade 3-4 TRAEs in 19.5% and 12.1% of patients, respectively. Patients with an ECOG PS 0-1 had significantly better OS and PFS in both treatment groups (p < 0.001). In the N + I group, OS was significantly better in patients with TRAEs (p = 0.020) and in those with the epithelioid subtype (p = 0.047), although PFS was not significantly different (p = 0.138 and p = 0.154, respectively). In the N group, both OS (p = 0.007) and PFS (p = 0.048) were significantly longer in patients with TRAEs.</p><p><strong>Conclusion: </strong>This study provides valuable real-world clinical evidence of the efficacy and safety of nivolumab plus ipilimumab and nivolumab monotherapy in Japanese patients with PM. These results support the use of ICIs as a viable treatment option for advanced or relapsed disease.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"705-717"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survey of healthcare professionals' awareness of appearance care for Japanese cancer patients and their institutions' appearance care systems: report from the Japan Society of Clinical Oncology.","authors":"Shiho Kuji, Keiko Nozawa, Shoko Toma, Harue Arao, Shigeru Imoto, Hiroaki Kajiyama, Atsuko Kitano, Yasuhiro Kodera, Ryuta Saito, Rika Sakai, Akinobu Taketomi, Robert Nakayama, Eiso Hiyama, Manabu Futamura, Motohiro Matsui, Masahito Yonemura, Mototsugu Oya, Nao Suzuki","doi":"10.1007/s10147-024-02685-y","DOIUrl":"10.1007/s10147-024-02685-y","url":null,"abstract":"<p><strong>Background: </strong>Appearance care enables cancer patients to maintain social connections during treatment, but it remains an unmet need in Japan. We surveyed healthcare professionals in Japan to collect information on their awareness of appearance care and their institutions' appearance care systems.</p><p><strong>Methods: </strong>From November 1 to December 13, 2022, we performed an online survey of 16,838 members of the Japan Society of Clinical Oncology.</p><p><strong>Results: </strong>We received responses from 807 members (671(83%) physicians; 65(8%) pharmacists; 45(6%) nurses; 22(3%) dentists; and 4(0.5%) others), 72% of whom were men and 28%, women. Among respondents, 93% (n = 749//807) had been asked by patients about appearance care, and 46% (n = 318/693) of the physicians and dentists had refused to perform treatment or changed it because of its effects on physical appearance. Only 59% (n = 410) of physicians and dentists were familiar with the term appearance care, but 100% (n = 45) of nurses and 97% (n = 63) of pharmacists were. Among all respondents, 26% reported that their institution had a specialized department and specific personnel for appearance care. In some cases, physicians and dentists had difficulty communicating correct information to patients, and other healthcare professionals compensated for this deficit.</p><p><strong>Conclusion: </strong>The survey revealed that physicians have low awareness of appearance care. It was suggested that communication and a team approach between physicians and other healthcare professionals is recommended. Each medical facility may be encouraged to establish a sustainable system for providing information on appearance care in that patients or medical personnel themselves can easily consult. Activities are also needed to raise awareness about appearance care among physicians.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"655-665"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal assessment of bone mineral density in prostate cancer patients: comparing metastatic and non-metastatic regions.","authors":"Takuto Hara, Hanako Nishimoto, Tomoaki Terakawa, Yasuyoshi Okamura, Yukari Bando, Hideto Ueki, Kotaro Suzuki, Yoji Hyodo, Jun Teishima, Koji Chiba, Ryosuke Kuroda, Hideaki Miyake","doi":"10.1007/s10147-025-02711-7","DOIUrl":"10.1007/s10147-025-02711-7","url":null,"abstract":"<p><strong>Objectives: </strong>Prostate cancer patients receiving androgen deprivation therapy (ADT) have increased risks of decreased bone mineral density (BMD). However, there are no established guidelines for assessing BMD in patients with bone metastases. The aim of this study was to assess the effects of ADT on bone health by comparing longitudinal changes in BMD between prostate cancer patients with and without bone metastases.</p><p><strong>Methods: </strong>A single-center observational study was conducted from February 2020 to January 2023 at Kobe University Hospital. BMD at the lumbar vertebrae, total hip, and femoral neck was measured at baseline, 6, and 12 months using dual-energy X-ray absorptiometry. Bones were classified into Metastatic Site (with metastases), Non-metastatic Sites (from patients with bone metastases), and Control (patients without metastases) groups. All patients received luteinizing hormone-releasing hormone antagonists or agonists plus oral ARSI or bicalutamide for 1 year.</p><p><strong>Results: </strong>Among the 78 patients, 35, 110, and 245 bones were classified into the Metastatic Site group, Non-metastatic Sites group, and Control group, respectively. The Metastatic Site group exhibited significantly higher T-scores compared with the other groups (P < 0.001). Repeated measures analysis revealed a statistically significant reduction in T-scores over time across all groups (P < 0.001). However, no significant interaction was observed between group classification and time (P = 0.817).</p><p><strong>Conclusion: </strong>The present study demonstrates that BMD changes at non-metastatic sites in patients with bone metastases are similar to those in patients without metastases. Monitoring BMD at non-metastatic sites may provide valuable insights into ADT's effects on bone health in prostate cancer patients.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"797-804"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11946959/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical utility of comprehensive genomic profiling for advanced pancreatic cancer: insights from real-world data analysis.","authors":"Eiichiro So, Hideyuki Hayashi, Keitaro Shimozaki, Sara Horie, Shotaro Kishimoto, Akihiko Chida, Yuki Saito, Kai Tsugaru, Kenro Hirata, Shigeki Tanishima, Hiroshi Nishihara, Takanori Kanai, Yasuo Hamamoto","doi":"10.1007/s10147-025-02713-5","DOIUrl":"10.1007/s10147-025-02713-5","url":null,"abstract":"<p><strong>Background: </strong>Precision medicine is a promising therapeutic strategy for pancreatic cancer. However, only a few patients are eligible for genotype-matched treatments because of the low detection rate of actionable genomic alterations, and the clinical application of comprehensive genomic profiling (CGP) in pancreatic cancer has not been completely investigated. CGP provides considerable information, including the prognosis and eligibility of patients for genotype-matched treatments, which can guide physicians' treatment strategies. This study aimed to investigate the contribution of CGP to patient outcomes.</p><p><strong>Methods: </strong>This single-center retrospective cohort study enrolled patients with recurrent or metastatic pancreatic cancer with adenocarcinoma or adenosquamous carcinoma who underwent systemic chemotherapy between April 2018 and April 2022. We reviewed the medical records for patient characteristics, survival, and genomic information. We compared overall survival (OS) between patients who received CGP (CGP group) and those who did not (non-CGP group).</p><p><strong>Results: </strong>Of 111 eligible patients, 59 underwent CGP. Median OS was significantly longer in the CGP than the non-CGP group (25.2 vs. 11.8 months; hazard ratio, 0.49; P = 0.0013). Six patients (10.2%) underwent genotype-matched treatments, with a median OS of 35.5 months, compared to 17.0 months for those who did not. The CGP group demonstrated a higher transition rate to subsequent chemotherapy than did the non-CGP group (76.3% vs. 48.1%, P = 0.0030).</p><p><strong>Conclusions: </strong>OS was prolonged in patients with pancreatic cancer who underwent CGP, probably due to its influence on physicians' treatment strategies. These findings highlight the importance of the proactive and timely implementation of CGP in patients with pancreatic cancer.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"728-737"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium.","authors":"Taizo Uchimoto, Kengo Iwatsuki, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Masanobu Saruta, Mamoru Hashimoto, Takafumi Minami, Yutaka Yamamoto, Shogo Yamazaki, Tomoaki Takai, Moritoshi Sakamoto, Yuki Nakajima, Kazuki Nishimura, Ryoichi Maenosono, Takuya Tsujino, Ko Nakamura, Tatsuo Fukushima, Kyosuke Nishio, Yuki Yoshikawa, Shutaro Yamamoto, Kosuke Iwatani, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Shunsuke Tsuduki, Kiyoshi Takahara, Kazutoshi Fujita, Takahiro Kimura, Yoshio Ohno, Ryoichi Shiroki, Haruhito Azuma","doi":"10.1007/s10147-025-02709-1","DOIUrl":"10.1007/s10147-025-02709-1","url":null,"abstract":"<p><strong>Background: </strong>Enfortumab vedotin (EV), an antibody-drug conjugate (ADC) targeting Nectin-4, has been available as standard care for metastatic urothelial carcinoma (mUC) patients who have progressed after platinum-based chemotherapy and checkpoint inhibitors (CPIs). However, the association between body mass index (BMI) and clinical outcomes for EV remains unknown.</p><p><strong>Methods: </strong>We analyzed the records of 123 mUC patients who received EV. The cohort was divided into low BMI (< 22, n = 65) and high BMI (≥ 22, n = 58) groups. Propensity score matching was performed to reduce clinical bias between the two groups.</p><p><strong>Results: </strong>In the total cohort (n = 123), the objective response rate (ORR) and disease control rate (DCR) were 46% and 68%, respectively. The ORR was significantly higher in the higher BMI group (62%, n = 58) compared to the lower BMI group (32%, n = 65). Among the pair-matched cohort (n = 100), despite reducing potential bias, the ORR remained significantly higher in the higher BMI group than in the lower BMI group (64% vs. 32%, p = 0.002). Both overall survival (OS) and radiographic progression-free survival (r-PFS) were longer in the higher BMI group compared to the lower BMI group (median OS: not reached vs. 8 months, p = 0.035; median r-PFS: 10 vs. 4 months, p < 0.001). On multivariate analyses, a higher BMI (≥ 22) was an independent predictor for achieving objective response and favorable OS in mUC patients treated with EV.</p><p><strong>Conclusions: </strong>The findings of this study suggest a potential association between high BMI and improved tumor response to EV in mUC patients with disease progression after platinum-based chemotherapy and CPIs.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"761-769"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing.","authors":"Shin Kobayashi, Yoshiaki Nakamura, Tadayoshi Hashimoto, Hideaki Bando, Eiji Oki, Takahiro Karasaki, Hidehito Horinouchi, Yukinori Ozaki, Hiroji Iwata, Taigo Kato, Hideaki Miyake, Akihiro Ohba, Masafumi Ikeda, Tatsuyuki Chiyoda, Kosei Hasegawa, Takao Fujisawa, Kazuto Matsuura, Kenjiro Namikawa, Shugo Yajima, Takayuki Yoshino, Kiyoshi Hasegawa","doi":"10.1007/s10147-024-02683-0","DOIUrl":"10.1007/s10147-024-02683-0","url":null,"abstract":"<p><p>Although the 5-year relative survival rates for resectable solid tumors have improved over the past few years, the risk of postoperative recurrence necessitates effective monitoring strategies. Recent advancements in molecular residual disease (MRD) testing based on circulating tumor DNA (ctDNA) analysis have shown considerable promise in the context of predicting recurrence; however, significant barriers to widespread clinical implementation remain-mainly, low awareness among healthcare professionals, high costs, and lack of standardized assays and comprehensive evidence. This position paper, led by the Japan Society of Clinical Oncology, aims to establish a common framework for the appropriate clinical use of MRD testing in a tumor type-agnostic manner. It synthesizes currently available evidence, reviews region-specific clinical trends, addresses critical clinical questions related to MRD testing, and offers recommendations to guide healthcare professionals, biotechnology and pharmaceutical companies, and regulatory authorities. These recommendations were developed based on a voting process involving 15 expert members, ensuring a consensus-driven approach. These findings underscore the importance of collaborative efforts among various stakeholders in enhancing the clinical utility of MRD testing. This project aimed to foster consensus and provide clear guidelines to support the advancement of precision medicine in oncology and improve patient outcomes in the context of perioperative care.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"605-654"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11946966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in fertility preservation treatments in Japan until 2023: analysis of the Japan Oncofertility Registry.","authors":"Takao Kawai, Miyuki Harada, Yoko Urata, Yuko Sanada, Youtaro Kaneda, Yasushi Takai, Yutaka Osuga, Nao Suzuki","doi":"10.1007/s10147-025-02725-1","DOIUrl":"10.1007/s10147-025-02725-1","url":null,"abstract":"<p><strong>Background: </strong>Fertility preservation for patients with cancer or other diseases who receive gonadotoxic treatment has gained importance as cancer survival rates increase. In Japan, a database for registering all fertility preservation patients, named the Japan Oncofertility Registry (JOFR), was established in 2018. This study aimed to analyze recent trends in fertility preservation in Japan utilizing data from the JOFR.</p><p><strong>Methods: </strong>Data was extracted from the JOFR for patients who consulted fertility preservation teams until May 2024. A descriptive analysis was conducted to examine trends in patient demographics, cancer types, fertility preservation treatments, complications, and outcomes. The data covered the period from diagnosis to fertility preservation and subsequent usage or disposal of frozen specimens.</p><p><strong>Results: </strong>A total of 11,510 patients were recorded, with 9491 undergoing fertility preservation treatments. The number of patients increased steadily after 2006. After 2021, the number of female patients was much higher than the number of male patients. The most common primary diseases were breast cancer among women and testicular tumors and leukemia among men. There were some complications including ovarian hyperstimulation syndrome (5.0%), bleeding (0.12%), and infections (0.05%) for women. Seven hundred and sixty clinical pregnancies were recorded, with 440 using preserved specimens. The discard rate was 16.3% for men and 3.7% for women.</p><p><strong>Conclusion: </strong>The study highlights recent trends in the growing number of cases undergoing fertility preservation in Japan. It also identifies several issues to be solved in fertility preservation in Japan, regarding its efficacy and safety, as well as the medical provision system.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"684-695"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11947001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic efficacy of immune-oncology combination therapy in advanced renal cell carcinoma without prior nephrectomy.","authors":"Kosuke Ueda, Naoki Ito, Yuya Sakai, Satoshi Ohnishi, Taishi Hirano, Hirofumi Kurose, Katsuaki Chikui, Keiichiro Uemura, Kiyoaki Nishihara, Makoto Nakiri, Shigetaka Suekane, Tsukasa Igawa","doi":"10.1007/s10147-025-02710-8","DOIUrl":"10.1007/s10147-025-02710-8","url":null,"abstract":"<p><strong>Background: </strong>Immuno-oncology (IO) combination therapies, including IO + IO or IO + vascular endothelial growth factor targeted therapies (VEGF-TT), have become the standard first-line treatment for advanced renal cell carcinoma (RCC). However, the optimal regimen for patients without prior nephrectomy remains unclear.</p><p><strong>Methods: </strong>Data from 99 patients with advanced RCC without nephrectomy, treated with VEGF-TT, IO + IO, or IO + VEGF-TT between May 2008 and May 2024, were retrospectively reviewed and analyzed. Patients were divided into VEGE-TT, IO + IO, and IO + VEGF-TT groups based on their first-line treatment, and survival and tumor response were compared.</p><p><strong>Results: </strong>All patients included in this study were categorized as either intermediate or poor risk according to the International Metastatic RCC Database Consortium risk classification. Among the 99 included patients, 41 initiated first-line therapy with VEGF-TT, 36 with IO + IO, and 22 with IO + VEGF-TT. The objective response rates were 17.5% for VEGF-TT, 38.9% for IO + IO, and 61.9% for IO + VEGF-TT. Notably, the IO + VEGF-TT group showed the greatest shrinkage of target kidney lesions (p = 0.0042). In multivariate analyses, bone metastasis (hazard ratio (HR) = 1.812, 95% confidence interval (CI) 1.017-3.228, p = 0.0436) and the first-line regimen (VEGF-TT vs IO + VEGF-TT: HR = 0.129, 95% CI 0.045-0.369, p = 0.0001) were independent prognostic factors for progression-free survival. The first-line regimen (VEGF-TT vs IO + VEGF-TT: HR = 0.303, 95% CI 0.104-0.879, p = 0.0279) independently affected overall survival.</p><p><strong>Conclusion: </strong>IO combination therapy, especially IO + VEGF-TT, has demonstrated a higher anti-tumor response in patients with advanced RCC without nephrectomy and may also be highly effective against primary renal tumors. Therefore, further studies are needed to improve patient survival and validate efficacy of IO combination therapy.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"770-779"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Palliative stereotactic body radiotherapy for spinal and non-spinal bone metastases: combining tradition and innovation.","authors":"Kei Ito, Naoki Nakamura","doi":"10.1007/s10147-025-02750-0","DOIUrl":"https://doi.org/10.1007/s10147-025-02750-0","url":null,"abstract":"<p><p>Bone metastases can cause pain, fractures, radiculopathy, and metastatic epidural spinal cord compression, all of which substantially impair patients' quality of life. Conventional external beam radiotherapy (cEBRT) has been the standard treatment for symptomatic bone metastases. While the effectiveness and safety of cEBRT are well established, it has certain limitations, including a short duration of pain relief, limited long-term tumor control, and suboptimal efficacy against radioresistant tumors. Over the past decade, stereotactic body radiotherapy (SBRT) has been explored as a palliative treatment for bone metastases. SBRT enables the delivery of high doses of radiation to bone lesions by maximizing dose conformality. This treatment characteristic yields several clinical advantages, including considerable pain relief, durable tumor control, and efficacy against radioresistant tumors. SBRT has the potential to overcome the limitations of cEBRT and represents a promising approach that could revolutionize the treatment of bone metastases. This review addresses three clinical scenarios: painful spinal metastases, painful non-spinal bone metastases, and metastatic epidural spinal cord compression. For each scenario, we summarized the evidence for cEBRT and SBRT, highlighting the utility and potential of SBRT as an emerging treatment option.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simple definition of biologically borderline resectable colorectal liver metastases based on early surgical failure.","authors":"Kenei Furukawa, Masashi Tsunematsu, Koichiro Haruki, Shinji Onda, Kyohei Abe, Michinori Matsumoto, Tomohiko Taniai, Mitsuru Yanagaki, Yoichi Toyama, Toru Ikegami","doi":"10.1007/s10147-025-02752-y","DOIUrl":"https://doi.org/10.1007/s10147-025-02752-y","url":null,"abstract":"<p><strong>Background: </strong>The benefit of neoadjuvant chemotherapy (NAC) in patients with resectable colorectal liver metastasis (CRLM) is debatable. This study aimed to establish a definition of biologically borderline resectable CRLM based on early surgical failure.</p><p><strong>Methods: </strong>One hundred forty-two patients who underwent upfront surgery for resectable CRLM were examined. Potential predictors of early surgical failure were investigated to establish a definition of biologically borderline resectable CRLM. The impact of NAC on overall survival (OS) in patients with borderline resectable CRLM was examined, as were predictors of OS.</p><p><strong>Results: </strong>Extrahepatic lesions (p < 0.01) and tumor ≥ 30 mm with carcinoembryonic antigen (CEA) concentration ≥ 20 ng/mL (p = 0.02) were independent predictors of early surgical failure. Borderline resectable CRLM was defined as extrahepatic lesions or tumor size ≥ 30 mm with CEA concentration ≥ 20 ng/mL. Fifty-eight patients had borderline resectable CRLM. Three-year OS was significantly higher in borderline resectable CRLM patients who received NAC than in those who did not (71.8% vs. 52.7%) and 5-year survival was also significantly higher in this group (62.8% vs. 25.5%).</p><p><strong>Conclusion: </strong>We have proposed a simple definition of biologically borderline resectable CRLM based on early surgical failure. NAC could be a good indication for patients who met the definition.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}